Fig 5. Up-regulated neurodegeneration markers in patients with epilepsy/nodding syndrome.
Levels of neurodegeneration markers of included individuals from plasma samples (CTRL, n = 17, EpNd, n = 32, OV+EpNd, n = 54) were determined using Luminex technology. Data depict concentrations of (A) amyloid-β 1–42 (B) TDP-43 and (C) neurogranin. Graphs show box whiskers with median, interquartile ranges and outliers. Since data were non-parametric, statistical significances between the indicated groups were obtained with Kruskal-Wallis followed by a Dunn’s multiple comparison test.